Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LSS | P48449 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13178389 | 0.81 | GNAI3 (0.52) | PIK3CDBRD4BRD2PKMPOLB | |
| SCHEMBL26375600 | 0.80 | LMNA (0.43) | SMN1; SMN2TP53 | |
| SCHEMBL13607427 | 0.79 | DRD2 (0.47) | PIK3CDBRD4BRD2PKMNPC1 | |
| SCHEMBL25664018 | 0.79 | PIK3CD (0.70) | PIK3CDBRD4BRD2NPC1RAB9A | |
| SCHEMBL27057345 | 0.78 | GBA1 (0.43) | SMN1; SMN2TP53 | |
| SCHEMBL1810789 | 0.78 | HRH3 (0.46) | MAOBSMN1; SMN2TP53 | |
| SCHEMBL6557871 | 0.76 | GRIA1 (0.36) | PIK3CDSMN1; SMN2L3MBTL1 | |
| SCHEMBL13600604 | 0.75 | BRD4 (0.39) | PIK3CDBRD4BRD2PKMNPC1 | |
| SCHEMBL25125955 | 0.74 | GNAI3 (0.57) | SMN1; SMN2TP53 | |
| SCHEMBL13600636 | 0.74 | TOP2A (0.34) | PKMMAOBNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632833-B2 | Anticancer agents | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20080287414-A1 | Mitotic Kinesin Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287414-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF18B | PIK3CD 610/4885BRD4 707/4885BRD2 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.